- Sep. 23, 2010 - NEW YORK --
According to Kalorama Information’
s World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
, oncology leads treatments under development. There are an estimated 550 projects in development from the top 50 companies which have the potential to add a value of more than $78 billion in additional revenues to the current pharmaceutical market by 2015.
Drugs in the oncology segment are expected to make a significant impact to current markets, increasing competition and providing advanced alternatives to current therapies. Cancer drugs in development could possibly make up nearly 33% of the potential value.
This is followed by development projects in the areas of cardiovascular and blood; neurotherapeutics;
respiratory and inflammation;
infectious diseases; gastrointestinal drugs; and other drugs—areas such as diabetes; sexual dysfunction;
dermatology not otherwise included in other segments; fertility drugs; hormones; osteoporosis treatments; renal disease; ocular treatments not otherwise included in other segments and other specialty segments. World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
can be obtained at http://www.kaloramainformation.com/Biopharmaceutical-Pipe...
# # #About Kalorama Information
Kalorama Information (www.kaloramainformation.com)
supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/
KaloramaInfo.Please direct all media inquiries to: